nach oben

Reviews in Endocrine and Metabolic Disorders

Erschienen in:

07.05.2019

Effect of resveratrol on metabolic syndrome components: A systematic review and meta-analysis

verfasst von: Sedigheh Asgary, Raheleh Karimi, Saeideh Momtaz, Rozita Naseri, Mohammad Hosein Farzaei

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

We summarized 16 controlled studies and evaluated the correlation of resveratrol supplementation with metabolic parameters such as the body weight, waist circumference (WC), systolic blood pressure (sbp), HDL, total cholesterol, triglyceride and glucose levels. This meta-analysis was carried out to determine the association between the resveratrol intake with metabolic parameters in metabolic syndrome patients. PubMed, Scopus, Cochrane and Google Scholar were searched from inception to December 2018 using relevant keywords. All articles were independently reviewed by two authors using predetermined selection criteria. We have selected the studies that investigated the effects of resveratrol on metabolic parameters. Of 16 studies, 10 were performed on human subjects, and in 6 studies animal models were used. Standard mean difference (SMD) with 95% confidence interval were determined using Der Simonian and Laird random-effects modeling, when there was a significant heterogeneity between studies. Funnel plot and Egger’s test were conducted to examine the risk of publication bias. Pooled effect sizes in human studies indicated a significant impact of resveratrol supplementation on glucose level [−1.73 (−2.99, −0.47); p = 0.007)] and WC [−1.73 (−2.79, −0.67); p = 0.001] compared with the control group. Also combining the results of studies on rat samples (n = 6), indicated significant effect of resveratrol on decreasing weight [−22.95 (−44.74, −1.17); p = 0.04], TGs [−6.76 (−11.10, −2.42); p = 0.001], sbp [−7.30 (−12.48, −2.13); p = 0.006], and it can influence significantly on increasing HDL level (4.75 (1.87, 7.63); p = 0.001). However, resveratrol was not significantly effective on total cholesterol in both samples. The results of subgroup analysis of human studies showed that resveratrol has significant effect on metabolic parameters (glucose level and WC) at the dosage of > 500 mg and with long-term interventions ≥ 10 weeks. Administration of resveratrol can meaningfully reduce the BW, WC, TGs, and glucose level, also it can increase HDL, but not total cholesterol.

Abete I, Goyenechea E, Zulet MA, Martinez JA. Obesity and metabolic syndrome: potential benefit from specific nutritional components. Nutr Metab Cardiovasc Dis. 2011;21(Suppl 2):B1–15. https://doi.org/10.1016/j.numecd.2011.05.001.CrossRefPubMed

Lifshitz F, Lifshitz JZ. Globesity: the root causes of the obesity epidemic in the USA and now worldwide. Pediatr Endocrinol Rev. 2014;12(1):17–34.PubMed

McLaren L. Socioeconomic status and obesity. Epidemiol Rev. 2007;29(1):29–48. https://doi.org/10.1093/epirev/mxm001.CrossRefPubMed

Marti A, Martinez-Gonzalez MA, Martinez JA. Interaction between genes and lifestyle factors on obesity. Proc Nutr Soc. 2008;67(1):1–8. https://doi.org/10.1017/S002966510800596X.CrossRefPubMed

Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One. 2012;7(8):e42529. https://doi.org/10.1371/journal.pone.0042529.CrossRefPubMedPubMedCentral

Alfaro FJ, Gavrieli A, Saade-Lemus P, Lioutas VA, Upadhyay J, Novak V. White matter microstructure and cognitive decline in metabolic syndrome: a review of diffusion tensor imaging. Metabolism. 2018;78:52–68. https://doi.org/10.1016/j.metabol.2017.08.009.CrossRefPubMed

Farzaei MH, El-Senduny FF, Momtaz S, Parvizi F, Iranpanah A, Tewari D, et al. An update on dietary consideration in inflammatory bowel disease: anthocyanins and more. Expert Rev Gastroenterol Hepatol. 2018;12(10):1–18. https://doi.org/10.1080/17474124.2018.1513322.CrossRef

Naseri R, Farzaei F, Haratipour P, Nabavi SF, Habtemariam S, Farzaei MH, et al. Anthocyanins in the Management of Metabolic Syndrome: a pharmacological and biopharmaceutical review. Front Pharmacol. 2018;9:1310. https://doi.org/10.3389/fphar.2018.01310.CrossRefPubMedPubMedCentral

Garcia-Conesa MT. Dietary polyphenols against metabolic disorders: how far have we progressed in the understanding of the molecular mechanisms of action of these compounds? Crit Rev Food Sci Nutr. 2017;57(9):1769–86. https://doi.org/10.1080/10408398.2014.980499.CrossRefPubMed

10.

Momtaz S, Hassani S, Khan F, Ziaee M, Abdollahi M. Cinnamon, a promising prospect towards Alzheimer's disease. Pharmacol Res. 2018;130:241–58. https://doi.org/10.1016/j.phrs.2017.12.011.CrossRefPubMed

11.

Vors C, Couillard C, Paradis ME, Gigleux I, Marin J, Vohl MC, et al. Supplementation with resveratrol and curcumin does not affect the inflammatory response to a high-fat meal in older adults with abdominal obesity: a randomized, placebo-controlled crossover trial. J Nutr. 2018;148(3):379–88. https://doi.org/10.1093/jn/nxx072.CrossRefPubMed

12.

Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32(12):1377–82. https://doi.org/10.1124/dmd.104.000885.CrossRefPubMed

13.

Baile CA, Yang JY, Rayalam S, Hartzell DL, Lai CY, Andersen C, et al. Effect of resveratrol on fat mobilization. Ann N Y Acad Sci. 2011;1215(1):40–7. https://doi.org/10.1111/j.1749-6632.2010.05845.x.CrossRefPubMed

14.

Alberdi G, Rodriguez VM, Miranda J, Macarulla MT, Arias N, Andres-Lacueva C, et al. Changes in white adipose tissue metabolism induced by resveratrol in rats. Nutr Metab (Lond). 2011;8(1):29. https://doi.org/10.1186/1743-7075-8-29.CrossRef

15.

Alberdi G, Rodriguez VM, Miranda J, Macarulla MT, Churruca I, Portillo MP. Thermogenesis is involved in the body-fat lowering effects of resveratrol in rats. Food Chem. 2013;141(2):1530–5. https://doi.org/10.1016/j.foodchem.2013.03.085.CrossRefPubMed

16.

Aguirre L, Fernandez-Quintela A, Arias N, Portillo MP. Resveratrol: anti-obesity mechanisms of action. Molecules. 2014;19(11):18632–55. https://doi.org/10.3390/molecules191118632.CrossRefPubMedPubMedCentral

17.

Fernandez-Quintela A, Milton-Laskibar I, Gonzalez M, Portillo MP. Antiobesity effects of resveratrol: which tissues are involved? Ann N Y Acad Sci. 2017;1403(1):118–31. https://doi.org/10.1111/nyas.13413.CrossRefPubMed

18.

Hu P, Zhao L, Chen J. Physiologically achievable doses of resveratrol enhance 3T3-L1 adipocyte differentiation. Eur J Nutr. 2015;54(4):569–79. https://doi.org/10.1007/s00394-014-0738-4.CrossRefPubMed

19.

Kang NE, Ha AW, Kim JY, Kim WK. Resveratrol inhibits the protein expression of transcription factors related adipocyte differentiation and the activity of matrix metalloproteinase in mouse fibroblast 3T3-L1 preadipocytes. Nutr Res Pract. 2012;6(6):499–504. https://doi.org/10.4162/nrp.2012.6.6.499.CrossRefPubMedPubMedCentral

20.

Kwon JY, Seo SG, Yue S, Cheng JX, Lee KW, Kim KH. An inhibitory effect of resveratrol in the mitotic clonal expansion and insulin signaling pathway in the early phase of adipogenesis. Nut Res (New York, NY). 2012;32(8):607–16. https://doi.org/10.1016/j.nutres.2012.06.014.CrossRef

21.

Chen Y, Siegel F, Kipschull S, Haas B, Frohlich H, Meister G, et al. miR-155 regulates differentiation of brown and beige adipocytes via a bistable circuit. Nat Commun. 2013;4:1769. https://doi.org/10.1038/ncomms2742.CrossRefPubMed

22.

Fischer-Posovszky P, Kukulus V, Tews D, Unterkircher T, Debatin KM, Fulda S, et al. Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr. 2010;92(1):5–15. https://doi.org/10.3945/ajcn.2009.28435.CrossRefPubMed

23.

Mader I, Wabitsch M, Debatin KM, Fischer-Posovszky P, Fulda S. Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis. FASEB J. 2010;24(6):1997–2009. https://doi.org/10.1096/fj.09-142943.CrossRefPubMed

24.

Szkudelski T, Szkudelska K. Resveratrol and diabetes: from animal to human studies. Biochim Biophys Acta. 2015;1852(6):1145–54. https://doi.org/10.1016/j.bbadis.2014.10.013.CrossRefPubMed

25.

Javkhedkar AA, Quiroz Y, Rodriguez-Iturbe B, Vaziri ND, Lokhandwala MF, Banday AA. Resveratrol restored Nrf2 function, reduced renal inflammation, and mitigated hypertension in spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2015;308(10):R840–6. https://doi.org/10.1152/ajpregu.00308.2014.CrossRefPubMedPubMedCentral

26.

Dolinsky VW, Chakrabarti S, Pereira TJ, Oka T, Levasseur J, Beker D, et al. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim Biophys Acta. 2013;1832(10):1723–33. https://doi.org/10.1016/j.bbadis.2013.05.018.CrossRefPubMed

27.

Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928.CrossRefPubMedPubMedCentral

28.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. https://doi.org/10.1136/bmj.327.7414.557.CrossRefPubMedPubMedCentral

29.

Richardson M, Garner P, Donegan S. Interpretation of subgroup analyses in systematic reviews: a tutorial. Clin Epidemiol Glob Health. 2018. https://doi.org/10.1016/j.cegh.2018.05.005.

30.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. https://doi.org/10.1136/bmj.315.7109.629.CrossRefPubMedPubMedCentral

31.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRefPubMed

32.

van der Made SM, Plat J, Mensink RP. Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial. PLoS One. 2015;10(3):e0118393. doi:0.1371/journal.pone.0118393.

33.

Mendez-del Villar M, Gonzalez-Ortiz M, Martinez-Abundis E, Perez-Rubio KG, Lizarraga-Valdez R. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2014;12(10):497–501. https://doi.org/10.1089/met.2014.0082.CrossRefPubMed

34.

Anton SD, Embry C, Marsiske M, Lu X, Doss H, Leeuwenburgh C, et al. Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study. Exp Gerontol. 2014;57:181–7. https://doi.org/10.1016/j.exger.2014.05.015.CrossRefPubMed

35.

Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(12):2092–103 e1-6. https://doi.org/10.1016/j.cgh.2014.02.024.CrossRefPubMed

36.

Fujitaka K, Otani H, Jo F, Jo H, Nomura E, Iwasaki M, et al. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nut Res (New York, NY). 2011;31(11):842–7. https://doi.org/10.1016/j.nutres.2011.09.028.CrossRef

37.

Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig Liver Dis. 2015;47(3):226–32. https://doi.org/10.1016/j.dld.2014.11.015.CrossRefPubMed

38.

Asghari S, Asghari-Jafarabadi M, Somi MH, Ghavami SM, Rafraf M. Comparison of calorie-restricted diet and resveratrol supplementation on anthropometric indices, metabolic parameters, and serum Sirtuin-1 levels in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. J Am Coll Nutr. 2018;37(3):223–33. https://doi.org/10.1080/07315724.2017.1392264.CrossRefPubMed

39.

Kjaer TN, Ornstrup MJ, Poulsen MM, Stodkilde-Jorgensen H, Jessen N, Jorgensen JOL, et al. No beneficial effects of resveratrol on the metabolic syndrome: a randomized placebo-controlled clinical trial. J Clin Endocrinol Metab. 2017;102(5):1642–51. https://doi.org/10.1210/jc.2016-2160.CrossRefPubMed

40.

Martinez-Abundis E, Mendez-Del Villar M, Perez-Rubio KG, Zuniga LY, Cortez-Navarrete M, Ramirez-Rodriguez A, et al. Novel nutraceutic therapies for the treatment of metabolic syndrome. World J Diabetes. 2016;7(7):142–52. https://doi.org/10.4239/wjd.v7.i7.142.CrossRefPubMedPubMedCentral

41.

Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612–22. https://doi.org/10.1016/j.cmet.2011.10.002.CrossRefPubMed

42.

Rivera L, Moron R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009;77(6):1053–63. https://doi.org/10.1016/j.bcp.2008.11.027.CrossRefPubMed

43.

Peredo-Escarcega AE, Guarner-Lans V, Perez-Torres I, Ortega-Ocampo S, Carreon-Torres E, Castrejon-Tellez V, et al. The combination of resveratrol and quercetin attenuates metabolic syndrome in rats by modifying the serum fatty acid composition and by upregulating SIRT 1 and SIRT 2 expression in white adipose tissue. Evidence-based Complementary and Alternative Medicine : eCAM. 2015;2015:474032. https://doi.org/10.1155/2015/474032.CrossRef

44.

Baek SH, Shin WC, Ryu HS, Lee DW, Moon E, Seo CS, et al. Creation of resveratrol-enriched rice for the treatment of metabolic syndrome and related diseases. PLoS One. 2013;8(3):e57930. https://doi.org/10.1371/journal.pone.0057930.CrossRefPubMedPubMedCentral

45.

Sutra T, Oiry C, Azay-Milhau J, Youl E, Magous R, Teissedre PL, et al. Preventive effects of nutritional doses of polyphenolic molecules on cardiac fibrosis associated with metabolic syndrome: involvement of osteopontin and oxidative stress. J Agric Food Chem. 2008;56(24):11683–7. https://doi.org/10.1021/jf802357g.CrossRefPubMed

46.

Robich MP, Chu LM, Chaudray M, Nezafat R, Han Y, Clements RT, et al. Anti-angiogenic effect of high-dose resveratrol in a swine model of metabolic syndrome. Surgery. 2010;148(2):453–62. https://doi.org/10.1016/j.surg.2010.04.013.CrossRefPubMed

47.

Benrick A, Maliqueo M, Miao S, Villanueva JA, Feng Y, Ohlsson C, et al. Resveratrol is not as effective as physical exercise for improving reproductive and metabolic functions in rats with dihydrotestosterone-induced polycystic ovary syndrome. Evidence-based complementary and alternative medicine : eCAM. 2013;2013:964070. https://doi.org/10.1155/2013/964070.CrossRef

48.

Konings E, Timmers S, Boekschoten MV, Goossens GH, Jocken JW, Afman LA, et al. The effects of 30 days resveratrol supplementation on adipose tissue morphology and gene expression patterns in obese men. Int J Obes. 2014;38(3):470–3. https://doi.org/10.1038/ijo.2013.155.CrossRef

49.

Wong RH, Howe PR, Buckley JD, Coates AM, Kunz I, Berry NM. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis. 2011;21(11):851–6. https://doi.org/10.1016/j.numecd.2010.03.003.CrossRefPubMed

50.

Liu Y, Ma W, Zhang P, He S, Huang D. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr. 2015;34(1):27–34. https://doi.org/10.1016/j.clnu.2014.03.009.CrossRefPubMed

51.

Liu K, Zhou R, Wang B, Mi MT. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr. 2014;99(6):1510–9. https://doi.org/10.3945/ajcn.113.082024.CrossRefPubMed

52.

Sahebkar A. Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2013;71(12):822–35. https://doi.org/10.1111/nure.12081.CrossRefPubMed

53.

Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell. 2006;127(6):1109–22.CrossRefPubMed

54.

Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337–42. https://doi.org/10.1038/nature05354.CrossRefPubMedPubMedCentral

55.

Szkudelska K, Nogowski L, Szkudelski T. Resveratrol, a naturally occurring diphenolic compound, affects lipogenesis, lipolysis and the antilipolytic action of insulin in isolated rat adipocytes. J Steroid Biochem Mol Biol. 2009;113(1–2):17–24. https://doi.org/10.1016/j.jsbmb.2008.11.001.CrossRefPubMed

56.

Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol. 2017;1(1):35. https://doi.org/10.1038/s41698-017-0038-6.CrossRefPubMedPubMedCentral

57.

Davidov-Pardo G, Joye IJ, McClements DJ. Encapsulation of resveratrol in biopolymer particles produced using liquid antisolvent precipitation. Part 1: preparation and characterization. Food Hydrocoll. 2015;45:309–16. https://doi.org/10.1016/j.foodhyd.2014.11.023.CrossRef

58.

Farzaei MH, Rahimi R, Nikfar S, Abdollahi M. Effect of resveratrol on cognitive and memory performance and mood: a meta-analysis of 225 patients. Pharmacol Res. 2018;128:338–44. https://doi.org/10.1016/j.phrs.2017.08.009.CrossRefPubMed

59.

Johnson JJ, Nihal M, Siddiqui IA, Scarlett CO, Bailey HH, Mukhtar H, et al. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol Nutr Food Res. 2011;55(8):1169–76. https://doi.org/10.1002/mnfr.201100117.CrossRefPubMedPubMedCentral

60.

Planas JM, Alfaras I, Colom H, Juan ME. The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. Arch Biochem Biophys. 2012;527(2):67–73. https://doi.org/10.1016/j.abb.2012.06.004.CrossRefPubMed

61.

Ajazuddin AA, Qureshi A, Kumari L, Vaishnav P, Sharma M, et al. Role of herbal bioactives as a potential bioavailability enhancer for active pharmaceutical ingredients. Fitoterapia. 2014;97:1–14. https://doi.org/10.1016/j.fitote.2014.05.005.CrossRefPubMed

62.

Nabavi SF, Russo GL, Daglia M, Nabavi SM. Role of quercetin as an alternative for obesity treatment: you are what you eat! Food Chem. 2015;179:305–10. https://doi.org/10.1016/j.foodchem.2015.02.006.CrossRefPubMed

63.

Arzola-Paniagua MA, Garcia-Salgado Lopez ER, Calvo-Vargas CG, Guevara-Cruz M. Efficacy of an orlistat-resveratrol combination for weight loss in subjects with obesity: a randomized controlled trial. Obesity (Silver Spring). 2016;24(7):1454–63. https://doi.org/10.1002/oby.21523.CrossRef

64.

Yun JW. Possible anti-obesity therapeutics from nature--a review. Phytochemistry. 2010;71(14–15):1625–41. https://doi.org/10.1016/j.phytochem.2010.07.011.CrossRefPubMed

65.

Bruckbauer A, Zemel MB. Synergistic effects of metformin, resveratrol, and hydroxymethylbutyrate on insulin sensitivity. Diabetes Metab Syndr Obes. 2013;6:93–102. https://doi.org/10.2147/DMSO.S40840.CrossRefPubMedPubMedCentral

Titel: Effect of resveratrol on metabolic syndrome components: A systematic review and meta-analysis
verfasst von: Sedigheh Asgary
Raheleh Karimi
Saeideh Momtaz
Rozita Naseri
Mohammad Hosein Farzaei
Publikationsdatum: 07.05.2019
Verlag: Springer US
Erschienen in: Reviews in Endocrine and Metabolic Disorders / Ausgabe 2/2019
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-019-09494-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypertonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Effect of resveratrol on metabolic syndrome components: A systematic review and meta-analysis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Prolactin and human weight disturbances: A puzzling and neglected association

Correction to: Statins, metformin, proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones: Immunomodulatory properties?

Functions of stem cells of thyroid glands in health and disease

Can blood glucose value really be referred to as a metabolic parameter?

Nutritional and non-nutritional agents that stimulate white adipose tissue browning

Role of growth factors and cytokines in diabetic foot ulcer healing: A detailed review

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin